Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis (ASQA): a Multicenter Post-marketing Surveillance Study

NCT04582084 is registered in ClinicalTrials.gov with AryoGen Pharmed Co. as lead sponsor.

NCT NCT04582084
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04582084 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis (ASQA): a Multicenter Post-marketing Surveillance Study
Lead sponsor
AryoGen Pharmed Co.
Phase
Observational
Overall status
Completed
Start date
April 4, 2014
Completion date
March 19, 2018
Enrollment
583 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis